<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716272</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1501</org_study_id>
    <nct_id>NCT02716272</nct_id>
  </id_info>
  <brief_title>Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients</brief_title>
  <acronym>MAPS2</acronym>
  <official_title>A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The sponsor raise the hypothesis that inhibition of immune PD-1+/- CTLA-4 check-point(s)&#xD;
      would delay tumor progression in patients with unresectable MPM, experiencing disease&#xD;
      progression after one or two lines of chemotherapy including at least first-line with&#xD;
      pemetrexed and platinum, without altering significantly the quality of life of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2016</start_date>
  <completion_date type="Actual">June 22, 2019</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control rate assessed by CT scan</measure>
    <time_frame>3-months</time_frame>
    <description>Tumor assessment (modified RECIST1.0 for mesothelioma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3-months</time_frame>
    <description>NCI CTC AE 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3-months</time_frame>
    <description>LCSS ( Lawrence County School System) Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognosis impact of blood biomarkers (exploratory studies)</measure>
    <time_frame>3-months</time_frame>
    <description>dosage in blood of numerous biomarkers and analysis of their prognosis impact</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>MONOTHERAPY ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMBINATION ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks</description>
    <arm_group_label>MONOTHERAPY ARM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab + Ipilimumab</intervention_name>
    <description>Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks</description>
    <arm_group_label>COMBINATION ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proved diagnosis of unresectable malignant pleural Mesothelioma (MPM)&#xD;
&#xD;
          2. Available (archival and/or fresh) pathological samples for centralized PD-L1&#xD;
             expression assessment by immunohistochemistry&#xD;
&#xD;
          3. Age ≥ 18 years old; male and female&#xD;
&#xD;
          4. ECOG Performance status 0-1&#xD;
&#xD;
          5. Weight loss &lt; 10% during last 3 months&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          7. Documented progression of the MPM, assessed by computed tomography (CT) -Scan.&#xD;
&#xD;
          8. Measurable disease, defined as at least 1 lesion (measurable) that can be accurately&#xD;
             assessed at baseline by CT-Scan and is suitable for repeated assessment using modified&#xD;
             Response Evaluation Criteria in Solid Tumors [RECIST] for pleural mesothelioma (Byrne&#xD;
             2004; Therasse 2006).&#xD;
&#xD;
          9. Previous treatment by 1 or 2 systemic chemotherapy lines (1 line of chemotherapy&#xD;
             considered if the patient received ≥2 cycles of this chemotherapy), including at least&#xD;
             one line with pemetrexed in combination with platinum agent (i.e. &quot;gold standard&#xD;
             chemotherapy in MPM; triplet including bevacizumab also accepted)&#xD;
&#xD;
         10. Written informed consent&#xD;
&#xD;
         11. Patients must have adequate organ function : creatinine clearance &gt; 50 mL/min&#xD;
             (Cockcroft formula), Neutrophiles count &gt; 1500/mm3; Platelets &gt; 100 000/mm3 ;&#xD;
             Hemoglobin &gt; 9 g/dL; hepatic enzymes &lt; 3N with total bilirubin ≤ 1.5 × ULN (upper&#xD;
             limit of normal) except subjects with documented Gilbert's syndrome (≤ 5 × ULN) or&#xD;
             liver metastasis, who must have a baseline total bilirubin ≤ 3.0 mg/dL&#xD;
&#xD;
         12. Recovered from all toxicities associated with prior treatment, to acceptable baseline&#xD;
             status, or a National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
             (NCI CTCAE v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk,&#xD;
             such as alopecia or vitiligo&#xD;
&#xD;
         13. Females of childbearing potential who are sexually active with a nonsterilized male&#xD;
             partner must use a highly effective method of contraception for 28 days prior to the&#xD;
             first dose of investigational product, and must agree to continue using such&#xD;
             precautions for 6 months after the final dose of investigational product; cessation of&#xD;
             contraception after this point should be discussed with a responsible physician.&#xD;
             Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable&#xD;
             methods of contraception. They must also refrain from egg cell donation for 6 months&#xD;
             after the final dose of investigational product. Men receiving nivolumab and who are&#xD;
             sexually active with women of childbearing potential will be instructed to adhere to&#xD;
             contraception for a period of 31 weeks after the last dose of nivolumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with primitive peritoneal, pericardial, testis or tunica vaginalis&#xD;
             mesothelioma&#xD;
&#xD;
          2. Patients with a recent history of other malignancies except adequately treated&#xD;
             non-melanoma skin cancer, and curatively treated in-situ cancer. Patients with&#xD;
             prostate adenocarcinoma diagnosed less than 5 years could be included in case of&#xD;
             localized prostate cancer with good outcome according the Amico classification: ≤ T2a&#xD;
             and Gleason Score ≤6 and PSA blood level ≤10 ng/ml, and treated with curative intent&#xD;
             (surgery or radiotherapy) without chemotherapy. Patients with history of solid tumors,&#xD;
             including adenocarcinoma, treated with curative intent and without any evidence of&#xD;
             disease &gt;5 years can be included as well.&#xD;
&#xD;
          3. Brain metastasis, except if surgically resected or treated with stereotaxic&#xD;
             radiotherapy with no evolution within the 3 months before inclusion, and asymptomatic&#xD;
             patient&#xD;
&#xD;
          4. History of primary immunodeficiency, history of organ transplant that requires&#xD;
             therapeutic immunosuppression and the use of immunosuppressive agents within 28 days&#xD;
             of randomization or a prior history of severe (grade 3 or 4) immune mediated toxicity&#xD;
             from other immune therapy.&#xD;
&#xD;
          5. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of randomization. Intranasal/inhaled or topical steroids, and adrenal replacement&#xD;
             steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of&#xD;
             active autoimmune disease.&#xD;
&#xD;
          6. Live attenuated vaccination administered within 30 days prior to randomization.&#xD;
&#xD;
          7. Known history of interstitial lung disease (asbestosis…) or CT-scan signs of&#xD;
             interstitial lung disease.&#xD;
&#xD;
          8. Subjects with an active, known or suspected autoimmune disease, including systemic&#xD;
             lupus erythematosis or Wegener's granulomatosis. Subjects with type I diabetes&#xD;
             mellitis, or hypothyroidism only requiring hormone replacement, or skin disorders&#xD;
             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, are&#xD;
             permitted to enroll.&#xD;
&#xD;
          9. Active or history of inflammatory bowel disease (eg, diverticulitis, colitis,&#xD;
             Crohn's), irritable bowel disease, celiac disease or other serious gastrointestinal&#xD;
             chronic conditions associated with diarrhea. Note that diverticulosis is permitted.&#xD;
&#xD;
         10. Patients with active or uncontrolled infections or with serious illnesses or medical&#xD;
             conditions which would not permit the patient to be managed according to the protocol.&#xD;
             This includes but is not limited to:&#xD;
&#xD;
               -  known prior history of active tuberculosis-disease;&#xD;
&#xD;
               -  known acute or chronic B or C hepatitis by serological evaluation. Patients with&#xD;
                  serological sequelae of hepatitis (antibodies test serologically positive for&#xD;
                  virus) without hepatitis could be included.&#xD;
&#xD;
               -  known Human immunodeficiency virus infection.&#xD;
&#xD;
         11. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or&#xD;
             any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint&#xD;
             pathways&#xD;
&#xD;
         12. The last dose of prior chemotherapy or radiation therapy (with the exception of&#xD;
             palliative radiotherapy) was received less than 3 weeks prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Scherpereel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intergroupe Francophone de Cancerologie Thoracique</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gérard Zalcman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intergroupe Francophone de Cancerologie Thoracique</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avignon - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon - CHU</name>
      <address>
        <city>Dijon</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble - CHU</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hopital Calmette</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulhouse - CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontoise - CH</name>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes - CHU</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen - CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Etienne Dolet</name>
      <address>
        <city>Saint-Nazaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulon - CHI</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse - CHU Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Pneumologie</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr/index.php/fr/la-recherche/item/2033-ifct-1501-maps2</url>
    <description>Official website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesothelioma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>nivolumab</keyword>
  <keyword>ipilimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

